Breast Cancer

Lloyd B. Gayle, MD, discusses current treatment options for patients who develop breast implant–associated anaplastic large cell lymphoma (ALCL).

Tucatinib has been approved in Switzerland for use in combination with trastuzumab and capecitabine for patients with previously treated metastatic HER2-positive breast cancer.

Melissa K. Accordino, MD, MS, discusses the utility of liquid biopsies in breast cancer.

Sara M. Tolaney, MD, MPH, discusses remaining questions with CDK4/6 inhibitors in hormone receptor–positive, HER2-negative metastatic breast cancer.

The American Society of Clinical Oncology and College of American Pathologists have further refined their recommendations for estrogen receptor and progesterone receptor testing protocols in patients with breast cancer.

Jean Wright, MD, discusses proton versus photon radiotherapy in breast cancer.

Lloyd B. Gayle, MD, discusses the current treatment of patients with breast implant–associated ALCL and remaining questions that need to be addressed.

Ruth O’Regan, MD, provides insight on how the COVID-19 crisis is impacting the care of patients with breast cancer.

In our exclusive interview, Dr. Hortobagyi shares his journey in the development of anthracyclines and taxanes, biphosphonates, and gene therapies in breast cancer, some of the challenges he has encountered along the way, and what he hopes to tackle in the rest of his monumental career.

Quantitative microelastography demonstrated increased sensitivity, specificity, and accuracy in detecting positive surgical margins in combination with optimal coherence tomography versus optimal coherence tomography alone in women who received breast-conserving surgery.

Lajos Pusztai, MD, DPhil, discusses the rationale for the phase 2 I-SPY 2 trial examining the addition of durvalumab and olaparib to neoadjuvant paclitaxel in HER2-negative breast cancer.

The addition of the novel innate immune activator, Imprime PGG, to checkpoint inhibition with pembrolizumab showed pronounced clinical benefit in patients with previously treated metastatic triple-negative breast cancer.

The addition of durvalumab (Imfinzi) and olaparib (Lynparza) to neoadjuvant paclitaxel was found to improve pathologic complete response rates compared with paclitaxel alone in patients with high-risk, HER2-negative stage II/III breast cancer.

Treatment with talazoparib did not demonstrate a statistically significant overall survival benefit in patients with BRCA1/2-mutated metastatic HER2-negative breast cancer.

Breast surgeon Kristin L. Brill MD, has joined the Sidney Kimmel Cancer Center – Jefferson Health as Enterprise Director of Breast Oncology.